Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Squamous Cell Carcinoma of the Head and Neck | Unmet Need | US/EU | 2021

Login to access report north_east
Contact sales account_box

For the past decade, Erbitux-based regimens have been the mainstay of treatment for recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN), but the launches of Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo are transforming the SCCHN treatment algorithm. However, despite the label expansions of these immune checkpoint inhibitors to include recurrent or metastatic non-nasopharyngeal SCCHN, more-efficacious first-line treatment options are needed to address the unmet needs pertaining to this subpopulation of SCCHN.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals in medical oncologists’ prescribing decisions for non-nasopharyngeal SCCHN?
  • What are the hidden opportunities that developers could leverage?
  • How do current therapies for non-nasopharyngeal SCCHN, such as Keytruda and Opdivo, perform on key clinical attributes for this patient population?
  • What are the greatest unmet needs and most attractive opportunities in the treatment of non-nasopharyngeal SCCHN?
  • What trade-offs are surveyed oncologists willing to make across key drug attributes and price when considering hypothetical target product profiles for non-nasopharyngeal SCCHN?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in February 2021

Key companies: Merck & Co., Bristol Myers Squibb, Eli Lilly

Key drugs: Erbitux, Keytruda, Opdivo

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…
north_east
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
north_east
Report
Vitiligo – Current Treatment – Treatment Algorithms: Claims Data Analysis – Vitiligo (US)
Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or loss of function of melanocytes. Its etiology and pathophysiology are not well understood but are believed to…
north_east
Report
Non-Small-Cell Lung Cancer – Geographic Focus: China – China In-Depth – Non-Small-Cell Lung Cancer
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in China. Treatment is based on biomarker status; patients with EGFR- and ALK-positive tumors generally receive…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east